Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at a price of CDN$0.05 per Unit.
Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder to acquire one additional Common Share at a price of CDN$0.12 per share for a period of 24 months from the closing date of the first tranche of the Offering, subject to the accelerated expiry provision described below.
If, during any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date of the Offering, the volume-weighted average trading price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange ("Exchange") is greater than or equal to CDN$0.15 per Common Share, the Company may accelerate the expiry date of the Warrants to the date that is 30 days following the date on which the Company issues a news release announcing the acceleration.
In connection with the first tranche of the Offering, the Company paid eligible finders aggregate cash finder's fees of approximately CDN$12,400 and issued 248,000 finder warrants (the "Finder Warrants"). Each Finder Warrant entitles the holder to purchase one Common Share at an exercise price of CDN$0.06 per share for a period of 24 months from the closing date of the first tranche.
The proceeds of the Offering are expected to be used for, sales, marketing, patient acquisition, physician education,
and commercialization initiatives; production and manufacturing expenses associated with ACP-01 treatments; regulatory and filing fees associated with submissions to the Ministry of Health and Wellness of the Commonwealth of The Bahamas; and general working capital and corporate purposes.
Certain directors of the Company participated, directly and indirectly, in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the Exchange. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a) of MI 61-101, respectively, on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds 25% of the Company's market capitalization calculated in accordance with MI 61-101.